The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Major depression has one of the highest economic burdens of any psychiatric disorder,” he pointed out. Now, the FDA has also approved Spravato for treating adults with MDD who have not responded ...

Walmart, CVS, Amazon and other well known retailers may have carried the recalled product, which the FDA calls out unique ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for ...

Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.

Spravato, a newly FDA-approved nasal spray, offers hope for individuals with treatment-resistant depression, a condition ...

Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...